FL 501
Alternative Names: FL-501Latest Information Update: 21 Jan 2023
At a glance
- Originator Adimab; Flame Biosciences
- Developer Leap Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Growth differentiation factor 15 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer